NEOGENOMICS INC — Director's Dealing 2019

Feb 28, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2019-02-26

Reporting Person: SHOVLIN ROBERT J. (President, Clinical Services)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-02-26	Common Stock	M	119348	$7.15	Acquired	242739	Direct
2019-02-26	Common Stock	M	66666	$7.52	Acquired	309405	Direct
2019-02-26	Common Stock	S	141879	$18.88	Disposed	167526	Direct
2019-02-27	Common Stock	S	44135	$19.23	Disposed	123391	Direct
2019-02-28	Common Stock	M	13986	$7.15	Acquired	137377	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-02-26	Stock Option (Right to Buy)	$7.15	M	119348	Disposed	2021-04-20	Common Stock (119348.0)	Direct
2019-02-28	Stock Option (Right to Buy)	$7.15	M	13986	Disposed	2021-04-20	Common Stock (13986.0)	Direct
2019-02-26	Stock Option (Right to Buy)	$7.52	M	66666	Disposed	2022-04-28	Common Stock (66666.0)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$8.03	2023-02-26	Common Stock (288500.0)	288500	Direct

Footnotes

F1: On April 20, 2016, Mr. Shovlin was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.

F2: On April 28, 2017, Mr. Shovlin was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.

F3: On February 26, 2018, Mr. Shovlin was granted 288,500 stock options. These options vest ratably over the first three anniversary dates of the grant date.